Filing Details

Accession Number:
0001209191-21-017869
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-03-04 17:00:21
Reporting Period:
2020-12-28
Accepted Time:
2021-03-04 17:00:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1623526 Stoke Therapeutics Inc. STOK Pharmaceutical Preparations (2834) 471144582
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1780082 Gene Liau C/O Stoke Therapeutics, Inc.
45 Wiggins Avenue
Bedford MA 01730
Evp Research & Preclinical Dev No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-12-28 8,000 $0.60 21,500 No 4 M Direct
Common Stock Disposition 2020-12-28 149 $58.73 21,351 No 4 S Direct
Common Stock Acquisiton 2021-03-02 5,195 $0.60 26,546 No 4 M Direct
Common Stock Disposition 2021-03-02 2,295 $62.46 24,251 No 4 S Direct
Common Stock Disposition 2021-03-02 2,900 $63.52 21,351 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2020-12-28 8,000 $0.00 8,000 $0.60
Common Stock Employee Stock Option (right to buy) Acquisiton 2021-03-02 40,800 $0.00 40,800 $60.00
Common Stock Employee Stock Option (right to buy) Disposition 2021-03-02 5,195 $0.00 5,195 $0.60
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
88,069 2028-04-02 No 4 M Direct
40,800 2031-03-01 No 4 A Direct
82,874 2028-04-02 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.00 to $62.93 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.13 to $63.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The option vested as to 1/4th of the total shares on January 16, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.
  5. The option vests as to 1/48th of the total shares on April 2, 2021 and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.